The recent identification of Breast Cancer 1 (BRCA1) and BRCA2 genes offers an opportunity for high-risk individuals to learn whether they may be genetically predisposed to develop breast and/or ovarian cancer. The purpose of this study was to examine how unaffected women, identified as BRCA positive and variant of uncertain significance (VUS) mutation carriers, managed their susceptibility to hereditary breast and ovarian cancer (HBOC). Thirty North American women ranging in age from 22 to 60 years responded to open-ended interviews. These interviews were analyzed using constant comparative method to generate a grounded theory. Managing Susceptibility was identified as the basic social process, which characterized how these unaffected wo...
Hereditary breast and/or ovarian cancer (HBOC) accounts for 5-10% of all breast and ovarian cancer d...
Women who inherit the BRCA1/2 gene have up to an 85% lifetime chance of developing breast cancer and...
Breast cancer is the most common malignancy among women in the western world. Most cases are sporadi...
The recent identification of Breast Cancer 1 (BRCA1) and BRCA2 genes offers an opportunity for high-...
Women found to carry mutations in the BRCA1 or BRCA2 genes have up to an 88% lifetime risk of breast...
Women found to carry mutations in the BRCA1 or BRCA2 genes have up to an 88% lifetime risk of breast...
Women with a family history of breast or ovarian cancers may be eligible for genetic testing to see ...
In the mid-1990s, genetic testing was introduced for two breast and ovarian cancer predisposition ge...
Women with a documented deleterious mutation in BRCA1 or BRCA2 are at substantially elevated risk fo...
Women with a family history of breast or ovarian cancers may be eligible for genetic testing to see ...
The recent identification of two breast and ovarian cancer susceptibility genes-BRCA1 and BRCA2- has...
Background Little is known about family members' interrelated decisions to seek genetic testing for...
The discovery of the association between breast and ovarian cancer and the BRCA genes and the develo...
Women who have a mutation in the BRCA1 or BRCA2 genes have up to an 87% lifetime risk of breast canc...
Background Females with BRCA 1/2 gene mutations have increased lifetime risk of breast and ovarian c...
Hereditary breast and/or ovarian cancer (HBOC) accounts for 5-10% of all breast and ovarian cancer d...
Women who inherit the BRCA1/2 gene have up to an 85% lifetime chance of developing breast cancer and...
Breast cancer is the most common malignancy among women in the western world. Most cases are sporadi...
The recent identification of Breast Cancer 1 (BRCA1) and BRCA2 genes offers an opportunity for high-...
Women found to carry mutations in the BRCA1 or BRCA2 genes have up to an 88% lifetime risk of breast...
Women found to carry mutations in the BRCA1 or BRCA2 genes have up to an 88% lifetime risk of breast...
Women with a family history of breast or ovarian cancers may be eligible for genetic testing to see ...
In the mid-1990s, genetic testing was introduced for two breast and ovarian cancer predisposition ge...
Women with a documented deleterious mutation in BRCA1 or BRCA2 are at substantially elevated risk fo...
Women with a family history of breast or ovarian cancers may be eligible for genetic testing to see ...
The recent identification of two breast and ovarian cancer susceptibility genes-BRCA1 and BRCA2- has...
Background Little is known about family members' interrelated decisions to seek genetic testing for...
The discovery of the association between breast and ovarian cancer and the BRCA genes and the develo...
Women who have a mutation in the BRCA1 or BRCA2 genes have up to an 87% lifetime risk of breast canc...
Background Females with BRCA 1/2 gene mutations have increased lifetime risk of breast and ovarian c...
Hereditary breast and/or ovarian cancer (HBOC) accounts for 5-10% of all breast and ovarian cancer d...
Women who inherit the BRCA1/2 gene have up to an 85% lifetime chance of developing breast cancer and...
Breast cancer is the most common malignancy among women in the western world. Most cases are sporadi...